Is ixazomib (Enleri) a chemotherapy drug or a targeted drug and analysis of clinical differences

Ixazomib (Ixazomib) is an oral proteasome inhibitor mainly used to treat multiple myeloma. It inhibits proteasome activity in tumor cells and hinders cellular protein degradation, thereby inducing cancer cell apoptosis and inhibiting proliferation. In terms of its mechanism of action, ixazomib is not a chemotherapy drug in the traditional sense, but a targeted anti-tumor drug that specifically targets the protein degradation pathways of tumor cells.

Compared with traditional chemotherapy drugs, ixazomib is more selective, mainly acts on rapidly proliferating malignant plasma cells, and causes relatively little damage to normal cells, so the side effects are usually lower than traditional chemotherapy. Traditional chemotherapy drugs broadly kill cells by interfering with DNA replication or cell division, while ixazomib achieves selective inhibition of tumors by targeting the proteasome.

In clinical applications, ixazomib is usually used in combination with lenalidomide or dexamethasone for patients with newly diagnosed or relapsed//span>refractory multiple myeloma. Clinical studies have shown that the drug combination can significantly prolong progression-free survival (PFS) and overall survival (OS), and the oral administration method improves patient compliance and facilitates long-term maintenance treatment.

It should be noted that although ixazomib is a targeted drug, side effects may still occur during treatment, such as gastrointestinal discomfort, thrombocytopenia, peripheral neuropathy, etc. Patients need to regularly monitor blood, renal function and nervous system status under the guidance of professional doctors to ensure medication safety and adjust dosage to achieve the best efficacy.

Reference materials:https://www.drugs.com/